Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer

Head and Neck

Volumn 34, Issue 10, 2012, Pages 1395-1402

  Han, Myung Woul ^a   Lee, Hee Jin ^a   Cho, Kyung Ja ^a   Kim, Jae Seung ^a   Roh, Jong Lyel ^a   Choi, Seung Ho ^a   Nam, Soon Yuhl ^a   Kim, Sang Yoon ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

2 18F fluoro 2 deoxy D glucose; FDG PET; tongue cancer; hypoxic markers; positron emission tomography

Indexed keywords

CARBONATE DEHYDRATASE; ERYTHROPOIETIN RECEPTOR; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TONGUE CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANOXIA; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; CARBONIC ANHYDRASES; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NECK DISSECTION; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ERYTHROPOIETIN; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TONGUE NEOPLASMS; TREATMENT OUTCOME;

EID: 84866419106     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21945     Document Type: Article

References (37)

1. Baba Y, Nosho K, Shima K, et al. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 2010; 176: 2292-2301.
2. Batmunkh E, Shimada M, Morine Y, et al. Expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) in patients with the gallbladder carcinoma. Int J Clin Oncol 2010; 15: 59-64.
3. Ilie M, Mazure NM, Hofman V, et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer 2010; 102: 1627-1635.
4. Osinsky S, Zavelevich M, Vaupel P,. Tumor hypoxia and malignant progression. Exp Oncol 2009; 31: 80-86.
5. Roh JL, Cho KJ, Kwon GY, et al. The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Oral Oncol 2009; 45: 63-68.
6. Ruan K, Song G, Ouyang G,. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009; 107: 1053-1062.
7. Denko NC,. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8: 705-713.
8. Mees G, Dierckx R, Vangestel C, Van de Wiele C,. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 2009; 36: 1674-1686.
9. Saga T, Koizumi M, Furukawa T, Yoshikawa K, Fujibayashi Y,. Molecular imaging of cancer: evaluating characters of individual cancer by PET/SPECT imaging. Cancer Sci 2009; 100: 375-381.
10. Toma-Dasu I, Dasu A, Brahme A,. Quantifying tumour hypoxia by PET imaging-a theoretical analysis. Adv Exp Med Biol 2009; 645: 267-272.
11. Wang K, Yorke E, Nehmeh SA, Humm JL, Ling CC,. Modeling acute and chronic hypoxia using serial images of 18F-FMISO PET. Med Phys 2009; 36: 4400-4408.
12. Wang W, Lee NY, Georgi JC, et al. Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer. J Nucl Med 3020; 51: 37-45.
13. Dunphy MP, Lewis JS,. Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med 2009; 50 Suppl 1: 106S-121S.
14. Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ,. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 2005; 32: 1384-1391. (Pubitemid 41746841)
15. Lapi SE, Voller TF, Welch MJ,. Positron emission tomography imaging of hypoxia. PET Clin 2009; 4: 39-47.
16. Postema EJ, McEwan AJ, Riauka TA, et al. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2- nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging 2009; 36: 1565-1573.
17. Schoder H, Fury M, Lee N, Kraus D,. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 2009; 50 Suppl 1: 74S-88S.
18. Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M,. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 2006; 80: 151-156. (Pubitemid 44301544)
19. Dierckx RA, Van de Wiele C,. FDG uptake, a surrogate of tumour hypoxia? Eur J Nucl Med Mol Imaging 2008; 35: 1544-1549.
20. Kaluz S, Kaluzova M, Liao SY, Lerman M, Stanbridge EJ,. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 2009; 1795: 162-172.
21. Silva P, Slevin NJ, Sloan P, et al. Prognostic significance of tumor hypoxia inducible factor-1alpha expression for outcome after radiotherapy in oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2008; 72: 1551-1559.
22. Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J,. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 2008; 35: 2294-2303.
23. Ong LC, Jin Y, Song IC, Yu S, Zhang K, Chow PK,. 2-[18F]-2-deoxy-D- glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II. Acta Radiol 2008; 49: 1145-1153.
24. Fassan M, Pizzi S, Sperti C, et al. 18F-FDG PET findings and GLUT-1 expression in IPMNs of the pancreas. J Nucl Med 2008; 49: 2070.
25. Gu J, Yamamoto H, Fukunaga H, et al. Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D- glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci 2006; 51: 2198-2205.
26. Mees G, Vangestel C, Dierckx R, Pauwels P, Van Meerbeeck J, Van de Wiele C,. Carbonic anhydrase IX expression correlates with FDG uptake by primary non-small cell lung cancer. Cancer Biother Radiopharm 2010; 25: 149-154.
27. Christian N, Deheneffe S, Bol A, et al. Is (18)F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer (14)C-EF3 in animal tumor models. Radiother Oncol 2010; 97: 183-188.
28. Hamada K, Tomita Y, Qiu Y, et al. 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II. Ann Nucl Med 2008; 22: 699-705.
29. Li SJ, Guo W, Ren GX, Huang G, Chen T, Song SL,. Expression of Glut-1 in primary and recurrent head and neck squamous cell carcinomas, and compared with 2-[18F]fluoro-2-deoxy-D-glucose accumulation in positron emission tomography. Br J Oral Maxillofac Surg 2008; 46: 180-186. (Pubitemid 351337627)
30. Zimny M, Gagel B, DiMartino E, et al. FDG-a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 2006; 33: 1426-1431. (Pubitemid 44885408)
31. van Baardwijk A, Dooms C, van Suylen RJ, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007; 43: 1392-1398. (Pubitemid 46874072)
32. Allal AS, Dulguerov P, Allaoua M, et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002; 20: 1398-1404. (Pubitemid 34177448)
33. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P,. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 2004; 59: 1295-1300. (Pubitemid 38954050)
34. Machtay M, Natwa M, Andrel J, et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 2009; 31: 195-201.
35. Miyawaki A, Ikeda R, Hijioka H, et al. SUVmax of FDG-PET correlates with the effects of neoadjuvant chemoradiotherapy for oral squamous cell carcinoma. Oncol Rep 2010; 23: 1205-1212.
36. Torizuka T, Tanizaki Y, Kanno T, et al. Prognostic value of 18F-FDG PET in patients with head and neck squamous cell cancer. AJR Am J Roentgenol 2009; 192: W156-160.
37. Schwartz DL, Rajendran J, Yueh B, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004; 130: 1361-1367. (Pubitemid 39603296)